Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas
This study is currently recruiting participants.
Verified May 2013 by Thomas Jefferson University
Sponsor:
Thomas Jefferson University
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT01458366
First received: September 26, 2011
Last updated: May 7, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | October 2017 |
| Estimated Primary Completion Date: | October 2015 (Final data collection date for primary outcome measure) |